跳转至内容
Merck
  • Fluconazole alters the polysaccharide capsule of Cryptococcus gattii and leads to distinct behaviors in murine Cryptococcosis.

Fluconazole alters the polysaccharide capsule of Cryptococcus gattii and leads to distinct behaviors in murine Cryptococcosis.

PloS one (2014-11-14)
Julliana Ribeiro Alves Santos, Rodrigo Assunção Holanda, Susana Frases, Mayara Bravim, Glauber de S Araujo, Patrícia Campi Santos, Marliete Carvalho Costa, Maira Juliana Andrade Ribeiro, Gabriella Freitas Ferreira, Ludmila Matos Baltazar, Aline Silva Miranda, Danilo Bretas Oliveira, Carolina Maria Araújo Santos, Alide Caroline Lima Fontes, Ludmila Ferreira Gouveia, Maria Aparecida Resende-Stoianoff, Jonatas Santos Abrahão, Antônio Lúcio Teixeira, Tatiane Alves Paixão, Danielle G Souza, Daniel Assis Santos
摘要

Cryptococcus gattii is an emergent human pathogen. Fluconazole is commonly used for treatment of cryptococcosis, but the emergence of less susceptible strains to this azole is a global problem and also the data regarding fluconazole-resistant cryptococcosis are scarce. We evaluate the influence of fluconazole on murine cryptococcosis and whether this azole alters the polysaccharide (PS) from cryptococcal cells. L27/01 strain of C. gattii was cultivated in high fluconazole concentrations and developed decreased drug susceptibility. This phenotype was named L27/01F, that was less virulent than L27/01 in mice. The physical, structural and electrophoretic properties of the PS capsule of L27/01F were altered by fluconazole. L27/01F presented lower antiphagocytic properties and reduced survival inside macrophages. The L27/01F did not affect the central nervous system, while the effect in brain caused by L27/01 strain began after only 12 hours. Mice infected with L27/01F presented lower production of the pro-inflammatory cytokines, with increased cellular recruitment in the lungs and severe pulmonary disease. The behavioral alterations were affected by L27/01, but no effects were detected after infection with L27/01F. Our results suggest that stress to fluconazole alters the capsule of C. gattii and influences the clinical manifestations of cryptococcosis.

材料
货号
品牌
产品描述

Sigma-Aldrich
庚烷, suitable for HPLC, ≥99%
Sigma-Aldrich
庚烷, ReagentPlus®, 99%
Sigma-Aldrich
庚烷, HPLC Plus, for HPLC, GC, and residue analysis, 99%
Sigma-Aldrich
庚烷, puriss. p.a., reag. Ph. Eur., ≥99% n-heptane basis (GC)
Sigma-Aldrich
左旋多巴, ≥98% (TLC)
Sigma-Aldrich
氟康唑, ≥98% (HPLC), powder
Sigma-Aldrich
庚烷, anhydrous, 99%
Sigma-Aldrich
庚烷, suitable for HPLC, ≥96%
USP
氟康唑, United States Pharmacopeia (USP) Reference Standard
Supelco
左多巴, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
氟康唑, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
庚烷, analytical standard
USP
左多巴, United States Pharmacopeia (USP) Reference Standard
Supelco
庚烷, Pharmaceutical Secondary Standard; Certified Reference Material
两性霉素 B, European Pharmacopoeia (EP) Reference Standard
左多巴, European Pharmacopoeia (EP) Reference Standard
氟康唑, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
庚烷, biotech. grade, ≥99%
氟康唑, European Pharmacopoeia (EP) Reference Standard